Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Obinutuzumab induces superior B-cell cytotoxicity to rituximab in rheumatoid arthritis and systemic lupus erythematosus patient samples
Venkat Reddy, Christian Klein, David Isenberg, et al.
Lara D. Veeken (2017) Vol. 56, Iss. 7, pp. 1227-1237
Open Access | Times Cited: 150

Showing 1-25 of 150 citing articles:

B cell depletion therapies in autoimmune disease: advances and mechanistic insights
Dennis S. W. Lee, Olga L. Rojas, Jennifer L. Gommerman
Nature Reviews Drug Discovery (2020) Vol. 20, Iss. 3, pp. 179-199
Open Access | Times Cited: 460
B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial
Richard Furie, Gustavo Aroca, Matthew D. Cascino, et al.
Annals of the Rheumatic Diseases (2021) Vol. 81, Iss. 1, pp. 100-107
Open Access | Times Cited: 282
Membranous nephropathy
Pierre Ronco, Laurence H. Beck, Hanna Dêbiec, et al.
Nature Reviews Disease Primers (2021) Vol. 7, Iss. 1
Open Access | Times Cited: 278
Targeting B Cells and Plasma Cells in Autoimmune Diseases
Katharina Hofmann, Ann‐Katrin Clauder, Rudolf A. Manz
Frontiers in Immunology (2018) Vol. 9
Open Access | Times Cited: 233
Pemphigus: Current and Future Therapeutic Strategies
Dario Didona, Roberto Maglie, Rüdiger Eming, et al.
Frontiers in Immunology (2019) Vol. 10
Open Access | Times Cited: 215
Systemic Lupus Erythematosus (SLE) Therapy: The Old and the New
Fabio Basta, Federica Fasola, Konstantinos Triantafyllias, et al.
Rheumatology and Therapy (2020) Vol. 7, Iss. 3, pp. 433-446
Open Access | Times Cited: 169
Expression, Role, and Regulation of Neutrophil Fcγ Receptors
Yu Wang, Friederike Jönsson
Frontiers in Immunology (2019) Vol. 10
Open Access | Times Cited: 149
Anti-rheumatoid drugs advancements: New insights into the molecular treatment of rheumatoid arthritis
Reda Ben Mrid, Najat Bouchmaa, Hassan Ainani, et al.
Biomedicine & Pharmacotherapy (2022) Vol. 151, pp. 113126-113126
Open Access | Times Cited: 86
Treatment of lupus nephritis: consensus, evidence and perspectives
Chi Chiu Mok, Y.K. Onno Teng, Ramesh Saxena, et al.
Nature Reviews Rheumatology (2023) Vol. 19, Iss. 4, pp. 227-238
Closed Access | Times Cited: 67
Precision medicine in systemic lupus erythematosus
Serena Fasano, Alessandra Milone, Giovanni Francesco Nicoletti, et al.
Nature Reviews Rheumatology (2023) Vol. 19, Iss. 6, pp. 331-342
Closed Access | Times Cited: 56
Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis
Richard Furie, Brad H. Rovin, Jay Garg, et al.
New England Journal of Medicine (2025)
Closed Access | Times Cited: 5
Therapeutic Antibodies: What Have We Learnt from Targeting CD20 and Where Are We Going?
Michael J. Marshall, Richard J. Stopforth, Mark S. Cragg
Frontiers in Immunology (2017) Vol. 8
Open Access | Times Cited: 150
Peripheral Blood B Cell Depletion after Rituximab and Complete Response in Lupus Nephritis
Liliana Michelle Gomez Mendez, Matthew D. Cascino, Jay Garg, et al.
Clinical Journal of the American Society of Nephrology (2018) Vol. 13, Iss. 10, pp. 1502-1509
Open Access | Times Cited: 144
New therapies for systemic lupus erythematosus — past imperfect, future tense
Gráinne Murphy, David Isenberg
Nature Reviews Rheumatology (2019) Vol. 15, Iss. 7, pp. 403-412
Open Access | Times Cited: 133
B cell targeted therapies in autoimmune disease
Jennifer L. Barnas, R. John Looney, Jennifer H. Anolik
Current Opinion in Immunology (2019) Vol. 61, pp. 92-99
Open Access | Times Cited: 104
Transplantation and immunosuppression: a review of novel transplant-related immunosuppressant drugs
Hakan Parlakpınar, Mehmet Günata
Immunopharmacology and Immunotoxicology (2021) Vol. 43, Iss. 6, pp. 651-665
Closed Access | Times Cited: 94
Engineering Anti-Tumor Monoclonal Antibodies and Fc Receptors to Enhance ADCC by Human NK Cells
Kate Dixon, Jianming Wu, Bruce Walcheck
Cancers (2021) Vol. 13, Iss. 2, pp. 312-312
Open Access | Times Cited: 65
Targeting B cells and plasma cells in autoimmune diseases: From established treatments to novel therapeutic approaches
Ana Merino‐Vico, Giulia Frazzei, Jan Piet van Hamburg, et al.
European Journal of Immunology (2022) Vol. 53, Iss. 1
Open Access | Times Cited: 44
B cell depletion therapies in autoimmune diseases: Monoclonal antibodies or chimeric antigen receptor-based therapy?
Zheng Zhang, Qian Xu, Liang Huang
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 34
Belimumab versus telitacicept in sequential treatment after rituximab for refractory lupus nephritis: a real-world multicentre study
Yi‐Ting Chen, Xin Lei, Jianhang Xu, et al.
Lupus Science & Medicine (2025) Vol. 12, Iss. 1, pp. e001296-e001296
Open Access | Times Cited: 1
Opportunities and limitations of B cell depletion approaches in SLE
Marit Stockfelt, Y.K. Onno Teng, Edward M Vital
Nature Reviews Rheumatology (2025)
Closed Access | Times Cited: 1
Advances in Targeted Therapy for Systemic Lupus Erythematosus: Current Treatments and Novel Approaches
Kaoru Saegusa, Yumi Tsuchida, Toshihiko Komai, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 3, pp. 929-929
Open Access | Times Cited: 1
Biologics in the Treatment of Lupus Erythematosus: A Critical Literature Review
Dominik Samotij, Adam Reich
BioMed Research International (2019) Vol. 2019, pp. 1-17
Open Access | Times Cited: 59
Leveraging Heterogeneity in Systemic Lupus Erythematosus for New Therapies
Marilyn E. Allen, Violeta Rus, Gregory L. Szeto
Trends in Molecular Medicine (2020) Vol. 27, Iss. 2, pp. 152-171
Open Access | Times Cited: 57
Advances in Understanding of Pathogenesis and Treatment of Immune-Mediated Kidney Disease: A Review
Sam Kant, Andreas Kronbichler, Purva Sharma, et al.
American Journal of Kidney Diseases (2021) Vol. 79, Iss. 4, pp. 582-600
Open Access | Times Cited: 53
Page 1 - Next Page

Scroll to top